Safety and efficacy of renal sympathetic denervation: a 9-year long-term follow-up of 24-hour ambulatory blood pressure measurements

Frontiers in Cardiovascular Medicine

Cardiovascular Medicine

Axel Schlitt¹  Michael Nußbaum²  Jochen Dutzmann²  Alexander Vogt²  Daniel Hoyer²  Jörn Tongers²  Daniel Sedding²  Alexander Plehn³ 

[1] Department of Cardiology and Diabetes, Paracelsus-Harz-Clinic Bad Suderode, Quedlinburg, Germany;Department of Internal Medicine III, University Hospital Halle (Saale), Halle (Saale), Germany;Department of Internal Medicine III, University Hospital Halle (Saale), Halle (Saale), Germany;Praxisklinik Salzatal, Salzatal, Germany;

关键词: renal denervation (RDN);    uncontrolled hypertension;    renal function;    ambulatory blood pressure;    long-term effect;   

DOI  :  10.3389/fcvm.2023.1210801

 received in 2023-04-23, accepted in 2023-05-26,  发布年份 2023

来源: Frontiers

【 摘 要 】

BackgroundRenal sympathetic denervation (RDN) has been shown to lower arterial blood pressure both in the presence and in the absence of antihypertensive medication in an observation period of up to 3 years. However, long-term results beyond 3 years are scarcely reported.MethodsWe performed a long-term follow-up on patients who were previously enrolled in a local renal denervation registry and who underwent radiofrequency RDN with the Symplicity Flex® renal denervation system between 2011 and 2014. The patients were assessed to evaluate their renal function by performing 24-hour ambulatory blood pressure measurement (ABPM), recording their medical history, and conducting laboratory tests.ResultsAmbulatory blood pressure readings for 24 h were available for 72 patients at long-term follow-up (FU) [9.3 years (IQR: 8.5–10.1)]. We found a significant reduction of ABP from 150.1/86.1 ± 16.9/12.0 mmHg at baseline to 138.3/77.1 ± 16.5/11.1 mmHg at long-term FU (P < 0.001 for both systolic and diastolic ABP). The number of antihypertensive medications used by the patients significantly decreased from 5.4 ± 1.5 at baseline to 4.8 ± 1.6 at long-term FU (P < 0.01). Renal function showed a significant but expected age-associated decrease in the eGFR from 87.8 (IQR: 81.0–100.0) to 72.5 (IQR: 55.8–86.8) ml/min/1.73 m2 (P < 0.01) in patients with an initial eGFR > 60 ml/min/1.73 m2, while a non-significant decrease was observed in patients with an initial eGFR < 60 ml/min/1.73 m2 at long-term FU [56.0 (IQR: 40.9–58.4) vs. 39.0 (IQR: 13.5–56.3) ml/min/1.73 m2].ConclusionsRDN was accompanied by a long-lasting reduction in blood pressure with a concomitant reduction in antihypertensive medication. No negative effects could be detected, especially with regard to renal function.

【 授权许可】

Unknown   
© 2023 Vogt, Dutzmann, Nußbaum, Hoyer, Tongers, Schlitt, Sedding and Plehn.